Ignyta, Inc.
(NASDAQ : RXDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.19%83.110.9%$974.61m
KITEKite Pharma, Inc.
0.02%179.3416.1%$742.24m
CELGCelgene Corporation
0.46%144.561.1%$500.05m
AMGNAmgen Inc.
0.15%186.031.1%$483.86m
BIIBBiogen Inc.
-0.14%318.001.2%$421.75m
REGNRegeneron Pharmaceuticals, Inc.
1.45%439.002.7%$359.48m
ALNYAlnylam Pharmaceuticals, Inc
1.81%115.8610.7%$250.17m
ALXNAlexion Pharmaceuticals, Inc.
0.39%143.381.9%$229.87m
JUNOJuno Therapeutics, Inc.
-4.78%42.9814.6%$225.42m
VRTXVertex Pharmaceuticals Incorporated
-1.38%149.171.9%$208.45m
INCYIncyte Corporation
-1.28%109.432.6%$204.99m
ILMNIllumina, Inc.
-0.63%200.143.5%$158.40m
BLUEBluebird Bio, Inc.
1.28%130.4019.3%$143.26m
BMRNBioMarin Pharmaceutical Inc.
-0.79%94.204.4%$136.30m
CLVSClovis Oncology, Inc.
-2.95%76.2518.0%$132.43m

Company Profile

Ignyta, Inc. is a precision oncology biotechnology company that engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. It plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. The company was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA.